Combination of an Insulin and a GLP-1 Agonist

• US 20170281733A1
• Filed: 11/01/2016
• Published: 10/05/2017
• Est. Priority Date: 10/17/2008
• Status: Active Grant

• Current Assignee: Sanofi-Aventis Deutschland GmbH (Sanofi )
• Original Assignee: Sanofi-Aventis Deutschland GmbH (Sanofi )
• Inventors: Werner, Ulrich, Rotthauser, Barbel
• Granted Patent: US 10,117,909 B2
• Time in Patent Office: Days
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 38/26 Glucagons
• CPC Class Codes: A61K 38/28 Insulins
• CPC Class Codes: A61P 1/18 for pancreatic disorders, e.g. pancreatic enzymes
• CPC Class Codes: A61P 3/04 Anorexiants; Antiobesity agents
• CPC Class Codes: A61P 3/08 for glucose homeostasis pancreatic hormones A61P5/48
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 5/00 Drugs for disorders of the endocrine system
• CPC Class Codes: A61P 5/48 of the pancreatic hormones
• CPC Class Codes: A61P 5/50 for increasing or potentiating the activity of insulin

Abstract

The invention relates to a drug comprising at least one insulin and at least one GLP-1 receptor agonist.

Claims

1. A pharmaceutical formulation comprising a combination of:

(a) insulin glargine or a pharmaceutically acceptable salt thereof, and

(b) desPro³⁶exendin-4(1-39)-Lys₆-NH₂ (AVE0010) or a pharmaceutically acceptable salt thereof;

wherein the concentration of insulin glargine is about 100 units/mL, and the concentration of AVE0010 is about 33 μ

g/mL; and

wherein the dosage of insulin glargine is between about 15 units and about 80 units, and the dosage of AVE0010 is between about 5 μ

g and about 20 μ

g.

2. The pharmaceutical formulation of claim 1,

wherein the dosage of insulin glargine is between about 15 units and about 60 units, and the dosage of AVE0010 is between about 5 μ

g and about 20 μ

g.